Jazz Pharmaceuticals Public Limited Company officer Patricia Carr filed a Form 144 notice of proposed sale of 1,413 shares of common stock, with an approximate sale date of November 4, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.

Key Highlights

  • Seller: Patricia Carr, an officer of Jazz Pharmaceuticals Public Limited Company, is the person for whose account the securities are to be sold.
  • Shares proposed for sale: 1,413 shares of common stock, with an aggregate market value of $326,909.51 as stated in the filing.
  • Shares outstanding: The filing reports 64,189,052 shares of common stock outstanding.
  • Acquisition sources: 1,250 shares were acquired via stock option exercise on November 4, 2026, and 163 shares were acquired through the Employee Stock Purchase Plan on May 29, 2026, both from the issuer.
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Prior sales: The filing reports nothing to report for securities sold during the past 3 months.
  • Exchange: Securities are listed on NASDAQ, trading under the issuer Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ as referenced; the filing identifies the exchange as NASDAQ).

Carr's Proposed Sale: Sources, Size, and Broker Details

According to the Form 144 filing dated November 4, 2026, Patricia Josephine Carr, identified as an officer of Jazz Pharmaceuticals Public Limited Company, provided notice of a proposed sale of 1,413 shares of common stock. The filing states the aggregate market value of those shares is $326,909.51, and that 64,189,052 shares of common stock are outstanding. The approximate date of sale listed in the filing is November 4, 2026, with Morgan Stanley Smith Barney LLC Executive Financial Services named as the broker.

The filing details two separate acquisition transactions underlying the shares proposed for sale. First, 1,250 shares were acquired on November 4, 2026 via a stock option exercise from the issuer, with payment made in cash on the same date. Second, 163 shares were acquired on May 29, 2026 through the Employee Stock Purchase Plan, also from the issuer and paid in cash on that date. Both acquisitions are listed as involving common stock.

The filing's securities sold section states "Nothing to Report" for any sales by the reporting person during the prior three months. Carr's signature on the form represents, as stated in the filing, that she "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." Jazz Pharmaceuticals is headquartered at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, according to the issuer address provided in the filing.

What Was Disclosed

A Form 144 notice filed November 4, 2026 discloses Jazz Pharmaceuticals officer Patricia Carr's proposed sale of 1,413 common shares with an aggregate market value of $326,909.51, sourced from a stock option exercise and an employee stock purchase plan acquisition.